Acadia Pharmaceuticals Inc [ACAD] stock is trading at $19.60, up 4.64%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACAD shares have gain 6.70% over the last week, with a monthly amount glided 6.46%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on January 03, 2025, when Guggenheim downgraded its rating to a Neutral and also revised its price target to $20 from $23. On August 07, 2024, downgrade downgraded it’s rating to Equal-Weight and revised its price target to $20 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $31 on June 27, 2024. Needham reiterated its recommendation of a Buy and reduced its price target to $32 on March 12, 2024. Mizuho downgraded its rating to Neutral for this stock on March 12, 2024, and downed its price target to $25. In a note dated January 30, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $40 on this stock.
Acadia Pharmaceuticals Inc [ACAD] stock has fluctuated between $14.15 and $26.78 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $19.60 at the most recent close of the market. An investor can expect a potential return of 2.04% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 929.24M for the trailing twelve months, which represents a growth of 18.28%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.26 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.04 points at the first support level, and at 18.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.90, and for the 2nd resistance point, it is at 20.21.
Ratios To Look Out For
For context, Acadia Pharmaceuticals Inc’s Current Ratio is 2.29. Also, the Quick Ratio is 2.11, while the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 3.51, the price to book ratio is 5.65 and price to earnings (TTM) ratio is 25.37.
Transactions by insiders
Recent insider trading involved Teehan Brendan, EVP, COO, HEAD OF COMMERCIAL, that happened on Nov 19 ’24 when 10329.0 shares were sold. PRINCIPAL ACCOUNTING OFFICER, Kihara James completed a deal on Nov 19 ’24 to sell 4073.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold 10259.0 shares on Nov 19 ’24.
